Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Capecitabine
Sponsor: ARCAGY/ GINECO GROUP